Statens Serum Institut

Ida Rosenkrands

Peter Andersen

Claus Aagaard

Anja Olsen

Else Marie Agger

Jesper Davidsen

Truc Thi Kim Thanh Hoang

Peter Birk Rasmussen

Karin Weldingh

Walter Florio

Peter Lawætz Andersen

Frank Follmann

Thomas Oettinger

Anette Stryhn

Søren Tetens Hoff

Rikke Nielsen

Peter Lawaetz Andersen

The present invention describes an efficient vaccine against a(Ct). The vaccine is based on recombinant fusion molecules that are capable of generating a high titered neutralizing antibody response that is protective against various Ct serovars. Our invention furthermore describe the combination of these antibody promoting fragments with Ct antigens that are targets for T cells with the aim to provide a vaccine that activate both arms of the immune system.

Vaccines againstsp

The present invention discloses in vitro and in vivo diagnostic methods with enhanced specificity and sensitivity for the detection of tuberculosis. The diagnostic reagents of the present invention can replace former mixtures/cocktails/pools of antigens comprising ESAT-6 but including ESAT6 improves the diagnosis even further.

Diagnostic reagents for improved in vivo or in vitro cell-mediated immunological diagnosis of tuberculosis

The present invention is directed to a fusion protein, antigen cocktails and immunological compositions such as vaccines against infections caused by virulent mycobacteria, e.g. byor. The fusion protein, antigen cocktails and immunological compositions are based on proteins secreted by the ESAT-6 secretion system 1 (ESX-1) and are among the most immunodominant(MTB) antigens.

M.tuberculosis vaccines

The present invention is directed to fusion proteins, antigen cocktails and immunological compositions such as vaccines against infections caused by virulent mycobacteria, e.g. byor. The fusion proteins or antigen cocktails are based on ESX secreted or associated proteins e.g. proteins secreted by the ESAT-6 secretion system 1 (ESX-1) which are among the most immunodominant(MTB) antigens.

[object Object]

The present invention relates to liposome formulations that are physically stable. In particular the present invention relates to steric stabilization of cationic liposomes by incorporating glycolipids into the liposomes. The stabilized liposomes can be used either as an adjuvant for antigenic components or as a drug delivery system. In particular the invention relates to vaccines with adjuvants in aqueous media for immunization, where the final product is stable.

Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids

The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldeoctadecylammonium-bromide/chloride (DDA) and a lipid extract fromBCG. The total lipid extract contains both apolar lipids, polar lipids, and lipids of intermediate polarity of which the apolar lipids were found to induce the most powerful immune responses. The total lipids may be extracted with chloroform/methanol and re-dissolved in water before the addition of surfactant. This preparation may be used to induce prominent cell-mediated immune responses in a mammal in order to combat pathogens, or as a treatment for cancer.

Adjuvant combinations of liposomes and mycobacterial lipids for immunization compositions and vaccines

Therapeutic vaccines comprising polypeptides expressed during the latent stage of mycobacteria infection are provided, as are multiphase vaccines, and methods for treating and preventing

Therapeutic TB vaccine

The present invention is based on the identification and characterization of a number of derived novel proteins and protein fragments (SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 17-23, 42, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72-86, 88, 90, 92, 94, 141, 143, 145, 147, 149, 151, 153, and 168-171). The invention is directed to the polypeptides and immunologically active fragments thereof, the genes encoding them, immunological compositions such as vaccines and skin test reagents containing the polypeptides. Another part of the invention is based on the surprising discovery that fusions between ESAT-6 and MPT59 are superior immunogens compared to each of the unfused proteins, respectively.

Growing community of inventors

Vaerlose, Denmark

Ida Rosenkrands